Latest Ratios: P/E Ratio 9.6x · EV/EBITDA 3.0x · ROE 11.2%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $227M | $438M | $431M | $401M | $541M | $575M | $578M | $392M | $653M | $383M | $165M |
| Enterprise Value | $73M | $283M | $276M | $252M | $443M | $472M | $460M | $407M | $628M | $434M | $203M |
| P/E Ratio → | 9.61 | 18.52 | 7.24 | 5.89 | 16.00 | 8.26 | 10.24 | — | 1.55 | — | — |
| P/S Ratio | 2.40 | 4.62 | 3.11 | 2.87 | 4.89 | 4.30 | 4.62 | 14.66 | 1.37 | 31.18 | 10.99 |
| P/B Ratio | 1.14 | 2.20 | 2.00 | 2.04 | 3.18 | 3.30 | 4.45 | 4.01 | 6.35 | — | — |
| P/FCF | 5.27 | 10.15 | 8.85 | 4.24 | 13.01 | 50.21 | 8.08 | — | 9.50 | — | — |
| P/OCF | 5.23 | 10.06 | 8.85 | 4.23 | 13.01 | 49.98 | 8.07 | — | 9.49 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.99 | 1.99 | 1.80 | 4.00 | 3.53 | 3.68 | 15.23 | 1.32 | 35.35 | 13.51 |
| EV / EBITDA | 3.01 | 11.67 | 3.92 | 2.99 | 10.25 | 5.27 | 5.41 | — | 1.77 | — | — |
| EV / EBIT | 3.08 | 9.31 | 3.63 | 2.87 | 10.04 | 5.28 | 6.01 | 72.83 | 1.47 | — | — |
| EV / FCF | — | 6.57 | 5.67 | 2.66 | 10.65 | 41.23 | 6.43 | — | 9.14 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.6% | 68.6% | 77.4% | 87.3% | 90.6% | 87.6% | 79.4% | 43.6% | 77.3% | -36.0% | -31.5% |
| Operating Margin | 25.1% | 25.1% | 50.4% | 59.8% | 38.5% | 66.7% | 67.6% | -8.7% | 74.4% | -153.6% | -206.9% |
| Net Profit Margin | 24.6% | 24.6% | 42.7% | 48.6% | 30.6% | 52.0% | 45.1% | -27.1% | 88.4% | -295.3% | -264.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.2% | 11.2% | 28.7% | 37.1% | 19.7% | 45.7% | 49.5% | -7.2% | 409.9% | — | — |
| ROA | 10.0% | 10.0% | 23.7% | 30.3% | 16.5% | 38.1% | 32.3% | -3.6% | 242.3% | -23.7% | -22.9% |
| ROIC | 33.7% | 33.7% | 97.0% | 105.3% | 44.6% | 159.1% | 101.1% | -1.8% | 342.3% | — | — |
| ROCE | 11.3% | 11.3% | 33.4% | 44.7% | 23.9% | 55.1% | 68.7% | -1.6% | 215.2% | -13.2% | -19.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.82 | 0.73 | — | — |
| Debt / EBITDA | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | 0.21 | — | — |
| Net Debt / Equity | — | -0.78 | -0.72 | -0.76 | -0.58 | -0.59 | -0.90 | 0.16 | -0.24 | — | — |
| Net Debt / EBITDA | -6.36 | -6.36 | -2.20 | -1.78 | -2.27 | -1.15 | -1.38 | — | -0.07 | — | — |
| Debt / FCF | — | -3.58 | -3.18 | -1.58 | -2.36 | -8.97 | -1.64 | — | -0.37 | — | — |
| Interest Coverage | — | — | — | — | — | — | 25.37 | 0.35 | 27.59 | -1.60 | -1.82 |
Net cash position: cash ($155M) exceeds total debt ($595169)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.83 | 11.83 | 9.12 | 4.42 | 8.63 | 6.85 | 13.70 | 1.96 | 10.70 | 5.49 | 5.00 |
| Quick Ratio | 9.10 | 9.10 | 7.16 | 3.23 | 6.81 | 6.21 | 11.77 | 1.86 | 10.44 | 5.05 | 3.11 |
| Cash Ratio | 8.61 | 8.61 | 6.13 | 2.77 | 4.59 | 3.38 | 11.25 | 0.71 | 8.88 | 2.92 | 2.08 |
| Asset Turnover | — | 0.43 | 0.57 | 0.55 | 0.57 | 0.62 | 0.83 | 0.13 | 2.34 | 0.08 | 0.09 |
| Inventory Turnover | 0.61 | 0.61 | 0.63 | 0.28 | 0.27 | 0.85 | 1.27 | 1.56 | 37.23 | 5.59 | 0.75 |
| Days Sales Outstanding | — | 12.59 | 55.69 | 55.12 | 149.61 | 228.42 | 9.76 | 56.89 | 1.50 | 53.61 | 76.82 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 19.0% | 9.9% | 9.9% | 8.0% | 6.1% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | 47.2% | 97.2% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 10.4% | 5.4% | 13.8% | 17.0% | 6.3% | 12.1% | 9.8% | — | 64.6% | — | — |
| FCF Yield | 19.0% | 9.9% | 11.3% | 23.6% | 7.7% | 2.0% | 12.4% | — | 10.5% | — | — |
| Buyback Yield | 0.2% | 0.1% | 0.2% | 2.8% | 2.4% | 4.5% | 4.9% | 0.0% | 0.6% | 0.2% | 0.3% |
| Total Shareholder Yield | 19.2% | 10.0% | 10.1% | 10.8% | 8.5% | 4.5% | 4.9% | 0.0% | 0.6% | 0.2% | 0.3% |
| Shares Outstanding | — | $72M | $72M | $72M | $74M | $76M | $79M | $82M | $83M | $79M | $57M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SIGA stock.
SIGA Technologies, Inc.'s current P/E ratio is 9.6x. The historical average is 12.0x. This places it at the 50th percentile of its historical range.
SIGA Technologies, Inc.'s current EV/EBITDA is 3.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 5.9x.
SIGA Technologies, Inc.'s return on equity (ROE) is 11.2%. The historical average is -76.9%.
Based on historical data, SIGA Technologies, Inc. is trading at a P/E of 9.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
SIGA Technologies, Inc.'s current dividend yield is 19.00%.
SIGA Technologies, Inc. has 68.6% gross margin and 25.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
SIGA Technologies, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Lumpy government procurement dependency
Metrics are mathematically derived from official filings.
Market Pricing Reflects Procurement Uncertainty
According to recent market data, SIGA trades at a forward P/E of 2.31, which, as noted in financial statements, suggests that investors are heavily discounting future earnings due to the extreme volatility inherent in the company's lumpy, government-dependent revenue recognition cycles compared to broader pharmaceutical peers.
The low valuation multiples appear to reflect a market skepticism regarding the sustainability of current earnings, given the reliance on episodic government contract milestones. Investors should monitor whether the current P/S of 2.97 represents a value opportunity or a permanent re-rating of the company's biodefense utility status.
Capital Efficiency Decaying Amidst Volatility
Based on historical financial data, SIGA's ROIC has experienced a sharp decline from 136.3% in 2023Q4 to -15.6% in 2026Q1, illustrating that the company is currently struggling to generate positive returns on its invested capital during periods of reduced government procurement activity and delivery gaps.
The dramatic swing in ROIC highlights the sensitivity of the business model to the timing of large-scale product deliveries. This decay in capital efficiency warrants further investigation into whether management can optimize asset utilization during the troughs of the federal procurement cycle.
Working Capital Cycles Obscure Performance
As reported in recent filings, the company's cash conversion cycle has expanded to 1562 days in 2026Q1, a metric that, according to financial statements, underscores the extreme difficulty in managing inventory and receivables when revenue is tied to infrequent, multi-year government stockpile replenishment milestones.
The massive fluctuations in the cash conversion cycle suggest that traditional efficiency metrics are poor indicators of operational health for this business. The high DIO levels indicate that inventory is held for extended periods, which is a structural necessity of the biodefense model rather than an operational failure.
Misapplication of Standard Growth Metrics
Based on an analysis of the company's business model, the most commonly misapplied metric is the trailing twelve-month (TTM) revenue growth rate, which, as indicated by financial statements, fails to account for the episodic nature of government procurement and obscures the underlying stability of the contract base.
Investors should instead focus on multi-year average revenue and the status of government procurement options to gauge true performance. Relying on quarterly or annual growth rates may lead to erroneous conclusions about the company's competitive position or the long-term durability of its sole-source status.